Scarica l'app Stockscreener
1.93
0.52%
0.01
Dopo l'orario di chiusura:
1.92
-0.01
-0.52%
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
H.C. Wainwright reiterates ProQR stock rating on platform data By Investing.com - Investing.com India
H.C. Wainwright reiterates ProQR stock rating on platform data - Investing.com
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results - MarketBeat
ProQR: Q2 Earnings Snapshot - 10TV
symbol__ Stock Quote Price and Forecast - CNN
ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results - tipranks.com
ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones - Quiver Quantitative
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProQR Therapeutics NV expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ProQR Therapeutics NV (PRQR) Stock News Today - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – MUN:0PQ - TradingView
ProQR Therapeutics (PRQR) CEO de Boer Daniel Anton Buys 200,000 Shares, Signaling Confidence - GuruFocus
PRQR|ProQR Therapeutics NV|Price:1.860|Chg%:+0.030 - TradingKey
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Proqr Therapeutics Insider Bought Shares Worth $353,960, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) CEO boosts stake with 200,000-share buy - Stock Titan
ProQR Therapeutics N.V. Revenue Breakdown – NASDAQ:PRQR - TradingView
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aberdeen Group (PRQR) discloses 6.33% ProQR Therapeutics stake via abrdn Inc. - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Buys 150,000 Shares - MarketBeat
ProQR Therapeutics N.V. Revenue Breakdown – LS:A12B97 - TradingView
ProQR Therapeutics NV (PRQR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PRQR|ProQR Therapeutics NV|Price:1.720|Chg%:-0.060 - TradingKey
PRQR|ProQR Therapeutics NV|Price:1.730|Chg%:+0.010 - TradingKey
ProQR Therapeutics NV (PRQR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProQR Therapeutics NV (PRQR) Institutional Confidence - TradingKey
ProQR Therapeutics NV (PRQR) Balance Sheet - TradingKey
ProQR Therapeutics NV (PRQR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProQR Therapeutics N.V. Revenue Breakdown – BMV:PRQR/N - TradingView
TradingKey - TradingKey
ProQR Therapeutics NV (PRQR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eli Lilly (NYSE: LLY) reports 21.99M-share beneficial stake in ProQR Therapeutics - Stock Titan
Privium Fund Management B.V. Increases Stake in ProQR Therapeuti - GuruFocus
Bart Filius Acquires Additional Shares in ProQR Therapeutics NV - GuruFocus
Form 4 ProQR Therapeutics N.V. For: 21 July By Investing.com - Investing.com South Africa
Proqr Therapeutics N.v. Insider Bought Shares Worth $257,925, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) director purchases 150,000 Ordinary Shares - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR Therapeutics (PRQR) Gains 1.8% as Shares Test Key Resistance Near $1.78Entry Point Alerts - dars.gov.et
PRQR Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Pipeline DevelopmentSlow Growth Warning - dars.gov.et
ProQR Therapeutics N.V. SEC Filing (Jul 16, 2026) - Stock Titan
ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet - Stock Titan
Aescap group and Patrick Krol report ProQR (PRQR) shareholdings - Stock Titan
Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares - MarketBeat
ProQR (PRQR) CEO lifts stake to 300,000 shares - Stock Titan
ProQR Therapeutics (PRQR) Faces Pressure at $1.73 After 1.7% DeclineSocial Sentiment - dars.gov.et
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ProQR (PRQR) CEO Daniel de Boer purchases 150,000 Ordinary Shares at $1.59 - Stock Titan
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):